# US 2003/0077609 A1 · Modified oligonucleotides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077609 A1
- Document ID: US20030077609A1
- Status: Published application
- Kind: A1
- Application number: 10/105,639
- Filed: 2002-03-25
- Published: 2003-04-24
- Earliest claimed: 2001-03-25
- Inventors: Mogens Havsteen Jakobsen; Henrik M. Pfundheller; Lars Kongsbak
- Web page: https://patentgrep.com/patent/US20030077609A1

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12Q 1/6832: Enhancement of hybridisation reaction
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Chimeric oligonucleotides are provided that contain non-modified DNA or RNA residues and modified nucleic acid residues. A modified nucleic acid residue is placed in the −1 position of the 3′ and/or 5′ end of the oligonucleotide. The oligonucleotides can exhibit significantly enhanced hybridization properties and improved capabilities as primers in nucleic acid extension and amplification reactions.

## Claims

### Claim 1

An oligonucleotide comprising non-modified nucleic acid residues and modified nucleic acid residues,
wherein the −1 residue of the oligonucleotides 3′ and/or 5′ ends is a modified nucleic acid.

### Claim 2 (depends on 1)

The oligonucleotide according to claim 1, wherein the −1 residue of the oligonucleotides 3′ end is a modified nucleic acid.

### Claim 3 (depends on 1, 2)

The oligonucleotide according to claim 1 or 2, wherein the −1 residues of the oligonucleotides 3′ and 5′ ends are a modified nucleic acid.

### Claim 4 (depends on 1, 2, 3)

The oligonucleotide according to any of the claims 1 to 3, comprising further modified nucleic acids

### Claim 5 (depends on 1, 2, 3, 4)

The oligonucleotide according to any of the claims 1 to 4, wherein greater than 50 percent of the total residues of the oligonucleotide are non-modified nucleic acids.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The oligonucleotide according to claims 1 to 5, comprising from 5 to 45 percent modified nucleic acid residues, based on total residues of the oligonucleotide.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The oligonucleotide according to any of the claims 1 to 6 suitable for use as a primer.

### Claim 8 (depends on 7)

The oligonucleotide according to claim 7, wherein the primer is adapted for use in an extension reaction involving a nucleic acid active enzyme.

### Claim 9 (depends on 7)

The oligonucleotide according to claim 7, wherein the primer is adapted for use in a nucleic acid amplification reaction.

### Claim 10 (depends on 9)

The oligonucleotide according to claim 9, wherein the nucleic acid amplification reaction is a multiplex polymerase chain reaction (PCR).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The oligonucleotide according to any of the claims 1 to 10, for discriminating between fully complementary target sequences and sequences having one or more mismatches, said oligonucleotide comprising a modified nucleic acid residue at a position opposite to the mismatch position of the target sequence.

### Claim 12 (depends on 11)

The oligonucleotide according to claims 11, wherein one or both nucleic acid residues flanking the modified nucleic acid positioned opposite the mismatch position of the target sequence are modified nucleic acid residues.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The oligonucleotide according to any of the claims 1 to 12, comprising a consecutive stretch of 3, 4, 5, or 6 modified nucleic acid residues.

### Claim 14 (depends on 11, 12, 13)

The oligonucleotide according to any of the claims 11 to 13, wherein the modified nucleic acid positioned opposite the mismatch position of the target sequence is comprised in the consecutive stretch of modified nucleic acid residues.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The oligonucleotide of any one of claims 1 through 14, wherein the oligonucleotide contains from about 5 to about 100 total residues.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The oligonucleotide of any one of claims 1 through 15, wherein the oligonucleotide contains from about 5 to about 50 total residues.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The oligonucleotide of any one of claims 1 through 16 wherein the oligonucleotide contains from about 5 to about 30 total residues.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The oligonucleotide of any one of claims 1 through 17 wherein the oligonucleotide contains from about 8 to about 15 total residues.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The oligonucleotide of any one of claims 1 through 18, wherein a modified nucleic acid residue of the oligonucleotide contains a modification at the 2′-position in the ribose.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The oligonucleotide of any one of claims 1 through 19, wherein the modified nucleic acid residue is an LNA residue.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The oligonucleotide of any one of claims 1 through 20, wherein the modified nucleic acid residue is an oxy-LNA residues.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The oligonucleotide of any one of claims 1 through 19, wherein the modified nucleic acid residue is selected from the group consisting of 2′-deoxy-2′-fluoro ribonucleotides, 2′-O-methyl ribonucleotides, 2′-O-methoxyethyl ribonucleotides, peptide nucleic acids, 5-propynyl pyrimidine ribonucleotides, 7-deazapurine ribonucleotides, 2,6-diaminopurine ribonucleotides, and 2-thio-pyrimidine ribonucleotides.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The oligonucleotide of any one of claims 1 through 22, wherein the non-modified residues contain deoxyribonucleotides.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The oligonucleotide of any one of claims 1 through 23 wherein the oligonucleotide is conjugated to one part of an affinity pair or to a compound selected from proteins, amplicons, enzymes, polysaccharides, antibodies, haptens, and peptides.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The oligonucleotide of any one of claims 1 through 24, wherein the oligonucleotide contains a fluorophor moiety and a quencher moiety, positioned in such a way that the hybridised state of the oligonucleotide can be distinguished from the unbound state of the oligonucleotide by an increase in the fluorescent signal from the nucleotide.

### Claim 26 (depends on 25)

The oligonucleotide of claim 25, wherein the oligonucleotide is adapted for use as a Taqman probe or Molecular Beacon.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of an oligonucleotide according to any of the claims 1 to 24 as a capture probe in a SNP assay.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of an oligonucleotide according to any of the claims 1 to 24 as a primer in a nucleic acid extension reaction.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of an oligonucleotide according to any of the claims 1 to 24 as a primer in a polymerase chain reaction (PCR).

### Claim 30 (depends on 29)

Use according to claim 29, wherein multiple primers are used in multiplex PCR.
